Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumors

home / between-the-lines / between-the-lines-personalized-circulating-tumor-dna-analysis-as-a-predictive-biomarker-in-solid

In this program, George Ansstas, MD, and Firas B. Badin, MD, discuss a recently published paper on ctDNA for analysis of immunotherapy efficacy in individual patients with solid tumor malignancies.

EP. 1: ctDNA as a Predictive Biomarker in Patients Treated with Pembrolizumab

George Ansstas, MD;Firas Badin, MD

August 24th 2021

Two medical oncologists summarize data on use of circulating tumor DNA as a predictive biomarker in solid tumor patients treated with pembrolizumab.

EP. 2: Potential Clinical Implications of ctDNA as a Predictive Biomarker

George Ansstas, MD;Firas Badin, MD

August 31st 2021

George Ansstas, MD, and Firas B. Badin, MD, discuss the potential clinical implications of using circulating tumor DNA as a predictive biomarker in solid tumor patients treated with immunotherapy.

EP. 3: Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy Response

George Ansstas, MD;Firas Badin, MD

September 24th 2021

CancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.